【24h】

Addiction to c-MYC in multiple myeloma

机译:多发性骨髓瘤成瘾于c-MYC

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

In multiple myeloma, c-MYC is activated and contributes to the malignant phenotype. Targeting MYC by short hairpin RNA induced cell death in myeloma cell lines; however, cell lines are generated from samples taken in advanced stages of the disease and may not reflect patient cells adequately. In this study, we used the selective small molecule inhibitor of MYCMAX heterodimerization, 10058-F4, on myeloma cell lines as well as primary myeloma cells, and we show that inhibition of c-MYC activity efficiently induces myeloma cell death. Moreover, in cocultures of cell lines with bone marrow stromal cells from myeloma patients, the inhibitor still induces apoptosis. Our results provide further evidence that myeloma cells are addicted to c-MYC activity and that c-MYC is a promising therapeutic target in multiple myeloma.
机译:在多发性骨髓瘤中,c-MYC被激活并有助于恶性表型。通过短发夹RNA靶向MYC诱导骨髓瘤细胞系中的细胞死亡;但是,细胞系是从疾病晚期取得的样本产生的,可能无法充分反映患者的细胞。在这项研究中,我们在骨髓瘤细胞系和原发性骨髓瘤细胞上使用了MYCMAX异源二聚化的选择性小分子抑制剂10058-F4,并且我们证明了抑制c-MYC活性可有效诱导骨髓瘤细胞死亡。此外,在骨髓瘤患者的骨髓基质细胞与细胞系的共培养中,该抑制剂仍然诱导细胞凋亡。我们的结果提供了进一步的证据,表明骨髓瘤细胞沉迷于c-MYC活性,并且c-MYC是多发性骨髓瘤中有希望的治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号